Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...
Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C provide the take-home messages from their session “Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem” at our...
In their presentation at the Practical Updates in Primary Care 2023 Virtual Series, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C reviewed the pathophysiological mechanisms of agitation...
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C provide the take-home messages from their session “Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem” at our...
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
In this interview, Emile d’Angremont, MSc, discusses the results of a recent study examining the use of cholinesterase inhibitors for the management of psychotic symptoms among patients with...
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C provide a preview of their session, "Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem ” at our Practical Updates...
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C Provide the take-home messages from their session “Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem” at our...
